Metformin exerts its glucose-lowering effect primarily through activation of AMP-activated protein kinase (AMPK).
AMPK reduces hepatic gluconeogenesis, improving insulin sensitivity and decreasing glucose production by liver cells.
This mechanism makes metformin a first-line drug in the management of type 2 diabetes.